Head-to-head evidence
albuterol / budesonide vs albuterol HFA (Proventil HFA)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
albuterol HFA (Proventil HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00635505 · Phase 3 · terminated
In this trial, Proventil-HFA is the established reference product that the investigational Armstrong's albuterol-HFA is being compared against, rather than the agent under primary evaluation itself, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · albuterol HFA (Proventil HFA)'s landscape